ARHGAP31

Across TCGA pan-cancer cohorts, ARHGAP31 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGAP31 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ARHGAP31 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGAP31 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, UCEC, and CESC are the cancer types where ARHGAP31 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	0.932	0.603	.005	18	view →
CESC	OS	Median	IV	0.095	0.592	.004	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARHGAP31–THYM (OS)

Open the THYM breakdown →